article Open AccessTop 1% cited

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

Gut · 2012 · Vol. 62(1) · pp. 112–120

Michael A. Jacobetz(Cancer Research UK Cambridge Center)Derek Chan(Cambridge University Hospitals NHS Foundation Trust)Albrecht Neeße(Cancer Research UK Cambridge Center)Tashinga E. Bapiro(Cambridge University Hospitals NHS Foundation Trust)Natalie Cook(Cancer Research UK Cambridge Center)Kristopher K. Frese(Cancer Research UK Cambridge Center)Christine Feig(Cancer Research UK Cambridge Center)Tomoaki Nakagawa(Cancer Research UK Cambridge Center)Meredith E. Caldwell(Cancer Research UK Cambridge Center)Heather Zecchini(Cancer Research UK Cambridge Center)Martijn P. Lolkema(Cancer Research UK Cambridge Center)Ping Jiang(Halozyme Therapeutics (United States))Anne Kultti(Halozyme Therapeutics (United States))Curtis B. Thompson(Halozyme Therapeutics (United States))Daniel C. Maneval(Halozyme Therapeutics (United States))Duncan I. Jodrell(Cancer Research UK Cambridge Center)G. J. Frost(Halozyme Therapeutics (United States))H. Michael Shepard(Halozyme Therapeutics (United States))Jeremy N. Skepper(University of Cambridge)David A. Tuveson✉(Cancer Research UK Cambridge Center)

View via DOI Full-text PDF

Abstract

The authors demonstrate that HA impedes the intratumoral vasculature in PDA and propose that its enzymatic depletion be explored as a means to improve drug delivery and response in patients with pancreatic cancer.

Proteoglycans and glycosaminoglycans research Pancreatic and Hepatic Oncology Research Fibroblast Growth Factor ResearchGemcitabinePancreatic cancerDrug deliveryMedicineCancer researchDesmoplasiaStromal cellPharmacologyAdenocarcinomaCancer

MeSH terms

GemcitabineAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDoxorubicinHyaluronic AcidHyaluronoglucosaminidaseImmunohistochemistryMice, TransgenicPancreatic NeoplasmsRecombinant ProteinsBiomarkers, TumorCell Adhesion MoleculesDrug Delivery Systems